BD Named Among America's Most Innovative Companies by Fortune

BD (Becton, Dickinson and Company) has been recognized by Fortune as one of America's Most Innovative Companies for 2025, placing in the top 25% of companies overall. This distinction celebrates BD’s commitment to developing groundbreaking medical technologies, improving operational processes, and nurturing an innovative corporate culture.

The ranking is based on surveys conducted with over 40,000 U.S. employees and more than 2,500 industry experts, evaluating companies across three dimensions: product innovation, process innovation, and innovation culture.

Tom Polen, BD’s chairman, CEO and president, highlighted the company's dedication to continuous innovation and improvement, emphasizing its impact on billions of patients worldwide and its role in delivering cutting-edge medical devices.

For more details about BD’s awards and achievements, visit news.bd.com/Award-news.

BD (Becton, Dickinson and Company) (NYSE: BDX) today announced the appointment of Gregory J. Hayes to its board of directors, effective March 26, 2025.

Becton, Dickinson and Company (BD) announced that the first patient has been treated in its clinical trial for the GalaFLEX LITE™ Scaffold, an investigational device aimed at reducing the recurrence of capsular contracture in breast implant revision surgery. The trial is a key step toward Premarket Approval from the U.S. Food and Drug Administration.

Capsular contracture is a common complication of implant-based breast surgery, occurring in 10 to 20 percent of cases and requiring surgical intervention in advanced stages. The recurrence rate after surgery can be as high as 54 percent. The BD STANCE Study (NCT05945329) is a multi-center, randomized controlled trial designed to assess the effectiveness of GalaFLEX LITE™ Scaffold, a bioabsorbable polymer implant made of Poly-4-Hydroxybutyrate (P4HB), in reducing capsular contracture recurrence and improving implant positioning.

The trial, which will enroll at least 250 patients across 40 sites, is being conducted with the FDA’s collaboration and will compare GalaFLEX LITE™ with conventional revision surgery. Patients will be randomized 2:1, receiving either the scaffold or standard care without additional supportive materials.

BD aims to establish GalaFLEX LITE™ as a transformative biomaterial for soft tissue reconstruction. The company is committed to scientific rigor and patient safety, with continued FDA engagement to expand women’s healthcare solutions.

For more details, visit www.galateasurgical.com.

Becton, Dickinson and Company (BD) held its 2025 Annual Meeting on January 28, 2025. Shareholders elected all board nominees for a one-year term. Ernst & Young was ratified as the independent auditor for fiscal year 2025. Shareholders also approved executive compensation on an advisory basis.